GlassScriptPhysician profile
Deirdre M Mooney
NPI 1003041468
$25,949.91
in general payments reported to CMS, 2019-2025
15 companies · $4,453 in 2025
The $4,453 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.12 · 2020: $146 · 2021: $40.02 · 2022: $768 · 2023: $14K · 2024: $6,556 · 2025: $4,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $1,756 · Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,135.00 |
| Travel and Lodging | $1,755.72 |
| Food and Beverage | $1,065.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19,130.37 | 2022-2024 | |
| Bridgebio Pharma, INC. | $4,185.00 | 2025 | Attruby |
| Abiomed | $1,238.74 | 2022-2024 | Impella |
| Abbott Laboratories | $482.25 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $228.37 | 2023-2025 | Camzyos |
| Janssen Scientific Affairs, LLC | $153.34 | 2022 | |
| Ancora Heart, INC. | $138.06 | 2023-2025 | Accucinch |
| Alnylam Pharmaceuticals INC. | $116.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $74.01 | 2020 | |
| Medtronic Vascular, INC. | $59.45 | 2019-2020 | |
| Sobi, INC | $40.02 | 2021 | |
| Eurofins Viracor, LLC | $38.83 | 2022 | |
| Paragonix Technologies, INC. | $33.38 | 2024 | Baroguard, Lungguard, Pancreaspak |
| Endotronix, INC. | $31.43 | 2024 | Cordella Pulomonary Artery Pressure Sensor |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.